Advertisement

Related Videos

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Varsha Gandhi, PhD, on Ibrutinib

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Apr
25
Today In Oncology
Long-Term Immunotherapy for Alveolar Soft Part Sarcoma
AMA Data Show Nearly 50 Percent of Surveyed Oncologists Reported Burnout in 2025
Unique Phase I NSCLC Trial Sites Decreasing in United States
Overall Survival With Addition of Relacorilant to Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer
Tislelizumab With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo